Arbutus Biopharma Corp  

(Public, TSE:TKM)   Watch this stock  
Find more results for TKM
22.97
Mar 3 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range     -
52 week 9.55 - 34.66
Open     -
Vol / Avg. 0.00/31,124.00
Mkt cap 502.11M
P/E     -
Div/yield     -
EPS -2.15
Shares 22.31M
Beta -0.58
Inst. own     -
Nov 4, 2015
Q3 2015 Arbutus Biopharma Corp Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Sep 10, 2015
Arbutus Biopharma Corp at Robert W Baird and Co Health Care Conference - 3:45PM EDT - Add to calendar
Aug 11, 2015
Arbutus Biopharma Corp at Wedbush PacGrow Healthcare Conference
Aug 6, 2015
Arbutus Biopharma Corp at Jefferies Hepatitis B Summit
Aug 5, 2015
Q2 2015 Tekmira Pharmaceuticals Corp Earnings Release
Jul 9, 2015
Tekmira Pharmaceuticals Corp Annual Shareholders Meeting
Jun 24, 2015
Tekmira Pharmaceuticals Corp at JMP Securities Life Sciences Conference
Jun 2, 2015
Tekmira Pharmaceuticals Corp at Jefferies Global Healthcare Conference
  

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -197.25% -90.95%
Operating margin -156.90% -78.59%
EBITD margin - -74.63%
Return on average assets -26.84% -22.63%
Return on average equity -34.40% -28.10%
Employees 85 -
CDP Score - -

Address

100-8900 Glenlyon Parkway
BURNABY, BC V5J 5J8
Canada
+1-604-4193200 (Phone)
+1-604-4193201 (Fax)

Website links

Description

Arbutus Biopharma Corp, formerly Tekmira Pharmaceuticals Corporation, is a Canada-based biopharmaceutical company focused on discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). The Company seeks to effect a cure by targeting the three pillars necessary to develop a curative regimen for HBV. This includes suppressing HBV replication within liver cells, stimulating and reactivating the body’s immune system so that it can mount an effective defense against the virus and eliminating the reservoir of viral genomic material known as covalently closed circular DNA, or cccDNA, that is the source of HBV persistence.